http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2011152517-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4965 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D241-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D241-24 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D241-24 |
| filingDate | 2010-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2011152517-A |
| titleOfInvention | Pyrazinecarboxamides as DGAT1 Inhibitors |
| abstract | 1. The compound of formula (I) or a pharmaceutically acceptable salt thereof, each r is independently 0 or 1, and each X is independently selected from linear C1-6 alkyl, C1-6 alkenyl, C1-6 alkynyl, C1-6 alkoxy, methoxymethyl, amino and cyano; each q is independently 0 or 1 and each X is independently selected from fluoro, chloro, bromo, amino, cyano, C1-6alkyl, Calkenyl, C1-6 alkynyl and Calkoxy; Y is selected from fluoro, chloro, bromo, cyano, C 1-6 alkyl and Calkoxy; n is 0, 1 or 2, and each Y is independently selected from fluoro, chloro, bromo, cyano, hydroxy, C1-6alkyl and alkoxy; p is 0, 1 or 2, and each Y independently represents is C1-6alkyl or, when p is 2, each Y can also join to form a cycloalkyl ring; Z is a carboxy or a Q group selected from —CONHSOMe or one of the following rings: or Z is —CONRbRc, where Rb and Rc are independently selected from hydrogen, C1-6 alkyl and C1-6 alkoxyethyl, or Rb and Rc are joined to form a morpholine ring or a C heterocyclic ring, and when Z is —CONRbRc, the C 1 alkyl group and the morpholine or C heterocyclic ring that can be formed may optionally be substituted a full carbon atom with a carboxy group or a Q group; and where any carbon atom in a linear C1-6 alkyl, C1-6 alkyl or C1-4 alkoxy containing a group as defined above may be optionally substituted with up to 3.2 fluorine atoms. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, wherein both r are 1 and each X is linear C 1-6 alkyl. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein Z is carboxy, —CONRbRc or a group 4. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein Z is carb |
| priorityDate | 2009-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 134.